October 3, 2023


Food, couldn't ask for more.

Clinical trial recruitment platform SubjectWell scores $35M

Clinical trial recruitment platform SubjectWell scores $35M

SubjectWell, a affected person recruitment system for scientific trials, announced it elevated $35 million in a Series B funding spherical led by Asset Administration Ventures.

Other individuals in the round contain Bertelsmann and present investors Healthy Ventures, Windham Enterprise Partners and Geekdom Fund.

In accordance to Crunchbase, the Texas-dependent company has elevated $46.8 million over seven funding rounds.


The new expenditure spherical will assistance SubjectWell accelerate its medical trial-recruitment get the job done, fund its recognition initiatives concerning post-approval solutions and help grow the firm’s support of most cancers analysis. 

“SubjectWell’s platform aggregates clients throughout scores of media channels, therefore developing an unparalleled pool of consented people – and can do so at scale. We’re happy to associate with SubjectWell and are thrilled to assistance the ongoing progress of the first viewers engagement platform for health care,” Thorsten Wirkes, senior vice president with Bertelsmann Investments, mentioned in a statement.

Current market SNAPSHOT

Numerous businesses are finding approaches to streamline the clinical trial participation process for contributors. 

In Might, decentralized scientific trial-organization Curebase, which presents patients a way to find and enroll in medical trials, indication consent kinds, accessibility telemedicine and timetable household visits, scored $40 million in a Sequence B round. The business also offers a web site-struggling with system aiding with participant recruitment and prescreening. 

A month later on, decentralized clinical trial organization THREAD declared it acquired CureClick, a platform for recruiting demo individuals that aims to enroll participants in decentralized scientific trials more effortlessly.

Abroad, Australian startup HealthMatch, a system for matching sufferers with medical trials, closed a Sequence C funding spherical of A$10 million ($6.8 million) that would enable the business expand its team and its platform’s reach across the U.S.